Brian Abrahams
Stock Analyst at RBC Capital
(2.27)
# 2,725
Out of 5,241 analysts
448
Total ratings
44.08%
Success rate
-4.21%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Maintains: Outperform | $80 → $82 | $54.39 | +50.76% | 21 | May 8, 2026 | |
| PTCT PTC Therapeutics | Maintains: Sector Perform | $81 → $82 | $71.47 | +14.73% | 25 | May 8, 2026 | |
| GILD Gilead Sciences | Maintains: Sector Perform | $123 → $122 | $129.58 | -5.85% | 36 | May 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $176 → $180 | $158.42 | +13.62% | 26 | May 6, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $541 → $543 | $436.95 | +24.27% | 59 | May 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $779 → $762 | $698.25 | +9.13% | 37 | Apr 30, 2026 | |
| BIIB Biogen | Maintains: Outperform | $213 → $222 | $192.95 | +15.06% | 43 | Apr 30, 2026 | |
| DMRA Damora Therapeutics | Initiates: Outperform | $40 | $24.60 | +62.60% | 1 | Apr 24, 2026 | |
| EVMN Evommune | Reiterates: Outperform | $48 | $22.92 | +109.42% | 1 | Apr 10, 2026 | |
| PHVS Pharvaris | Maintains: Outperform | $52 → $51 | $30.43 | +67.60% | 2 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $83 → $82 | $81.14 | +1.06% | 4 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $13 | $17.55 | -25.93% | 5 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $18 → $6 | $4.57 | +31.29% | 6 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $30 | $21.40 | +40.19% | 5 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $11 → $12 | $9.76 | +22.95% | 13 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $95 → $92 | $95.31 | -3.47% | 25 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $13 | $9.02 | +44.12% | 20 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $30 | $15.86 | +89.21% | 1 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $40 | $21.39 | +87.00% | 2 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $36 | $20.99 | +71.51% | 1 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $103 | $82.21 | +25.29% | 2 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $40.32 | -40.48% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $7 | $1.84 | +280.43% | 7 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $22 | $13.72 | +60.35% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $53 | $11.03 | +380.51% | 9 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $1.5 → $1 | $0.50 | +98.41% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $3 → $2 | $1.15 | +73.91% | 14 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $19 | $7.67 | +147.72% | 13 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $23 | $17.55 | +31.05% | 35 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $84 | $27.55 | +204.90% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $227.72 | -37.20% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $35.44 | +12.87% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $13.41 | +11.86% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $4.02 | +124.16% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $25.00 | - | 4 | Dec 4, 2017 |
Xenon Pharmaceuticals
May 8, 2026
Maintains: Outperform
Price Target: $80 → $82
Current: $54.39
Upside: +50.76%
PTC Therapeutics
May 8, 2026
Maintains: Sector Perform
Price Target: $81 → $82
Current: $71.47
Upside: +14.73%
Gilead Sciences
May 8, 2026
Maintains: Sector Perform
Price Target: $123 → $122
Current: $129.58
Upside: -5.85%
Neurocrine Biosciences
May 6, 2026
Maintains: Outperform
Price Target: $176 → $180
Current: $158.42
Upside: +13.62%
Vertex Pharmaceuticals
May 5, 2026
Maintains: Outperform
Price Target: $541 → $543
Current: $436.95
Upside: +24.27%
Regeneron Pharmaceuticals
Apr 30, 2026
Maintains: Sector Perform
Price Target: $779 → $762
Current: $698.25
Upside: +9.13%
Biogen
Apr 30, 2026
Maintains: Outperform
Price Target: $213 → $222
Current: $192.95
Upside: +15.06%
Damora Therapeutics
Apr 24, 2026
Initiates: Outperform
Price Target: $40
Current: $24.60
Upside: +62.60%
Evommune
Apr 10, 2026
Reiterates: Outperform
Price Target: $48
Current: $22.92
Upside: +109.42%
Pharvaris
Apr 6, 2026
Maintains: Outperform
Price Target: $52 → $51
Current: $30.43
Upside: +67.60%
Mar 3, 2026
Maintains: Sector Perform
Price Target: $83 → $82
Current: $81.14
Upside: +1.06%
Mar 2, 2026
Maintains: Sector Perform
Price Target: $12 → $13
Current: $17.55
Upside: -25.93%
Mar 2, 2026
Downgrades: Sector Perform
Price Target: $18 → $6
Current: $4.57
Upside: +31.29%
Feb 26, 2026
Maintains: Outperform
Price Target: $31 → $30
Current: $21.40
Upside: +40.19%
Feb 20, 2026
Maintains: Sector Perform
Price Target: $11 → $12
Current: $9.76
Upside: +22.95%
Feb 11, 2026
Maintains: Sector Perform
Price Target: $95 → $92
Current: $95.31
Upside: -3.47%
Jan 30, 2026
Maintains: Outperform
Price Target: $14 → $13
Current: $9.02
Upside: +44.12%
Jan 29, 2026
Maintains: Outperform
Price Target: $28 → $30
Current: $15.86
Upside: +89.21%
Jan 23, 2026
Maintains: Outperform
Price Target: $33 → $40
Current: $21.39
Upside: +87.00%
Jan 23, 2026
Maintains: Outperform
Price Target: $20 → $36
Current: $20.99
Upside: +71.51%
Dec 16, 2025
Maintains: Outperform
Price Target: $70 → $103
Current: $82.21
Upside: +25.29%
Dec 1, 2025
Downgrades: Underperform
Price Target: $24
Current: $40.32
Upside: -40.48%
Dec 1, 2025
Upgrades: Outperform
Price Target: $4 → $7
Current: $1.84
Upside: +280.43%
Nov 21, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $13.72
Upside: +60.35%
Nov 13, 2025
Maintains: Outperform
Price Target: $55 → $53
Current: $11.03
Upside: +380.51%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $1.5 → $1
Current: $0.50
Upside: +98.41%
Nov 7, 2025
Maintains: Sector Perform
Price Target: $3 → $2
Current: $1.15
Upside: +73.91%
Nov 4, 2025
Maintains: Outperform
Price Target: $30 → $19
Current: $7.67
Upside: +147.72%
Jul 17, 2025
Maintains: Sector Perform
Price Target: $25 → $23
Current: $17.55
Upside: +31.05%
Apr 22, 2025
Reiterates: Outperform
Price Target: $84
Current: $27.55
Upside: +204.90%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $227.72
Upside: -37.20%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $35.44
Upside: +12.87%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.41
Upside: +11.86%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $4.02
Upside: +124.16%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $25.00
Upside: -